Biologic rebate contracts for insulin, human
Original notice title
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-11 - Insulin, normal (human)
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
30 / 100
Risk factors
No estimated value or framework maximum available; cannot assess potential revenue.
Procurement documents were not analyzed; key terms (e.g., discount rates, conditions) unknown.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Supplies contract
- 2 lots
- Duration until Jul 2027
- Establishment of discount agreements for human insulin (normal) as per § 130a Abs. 8 SGB V
- Two dosage forms: cylinder ampoules and pre-filled pens
Show full summary
Open House procedure by Techniker Krankenkasse (TK) for discount agreements on human insulin (normal). Two lots: cylinder ampoules and pre-filled pens. Contract duration max 24 months from Aug 2025. No estimated value provided. No award criteria defined (stated irrelevant). Eligibility limited to pharmaceutical entrepreneurs with valid marketing authorization. Submission via email or post at any time during contract term.
Risks
No estimated value or framework maximum available; cannot assess potential revenue.
Procurement documents were not analyzed; key terms (e.g., discount rates, conditions) unknown.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur within the meaning of § 4 Abs. 18 AMG
- Valid marketing authorization for the offered medicinal product
Eligibility
- Declaration of eligibility and reliability (Anlage 4)
Requirements may be incomplete.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (2)
LOT-0001
Insulin, normal (human) (Cylinder ampoules)
Open House for discount agreements on human insulin in cylinder ampoule dosage form. Contract duration 24 months, no guarantee of exclusivity.
Location
Duration
Category
Award details
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zum Wirkstoff Insulin, normal (human) [zur Aufteilung in Lose siehe bei den Angaben zu den Losen] zu schließen.
Value note
Show original TED data
Original lot title
Insulin, normal (human) (Darreichungsform: Zylinderampullen)
Original TED description
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zum Wirkstoff Insulin, normal (human) [zur Aufteilung in Lose siehe bei den Angaben zu den Losen] zu schließen.
LOT-0002
Insulin, normal (human) (Pre-filled pen)
Open House for discount agreements on human insulin in pre-filled pen dosage form. Contract duration 24 months, no guarantee of exclusivity.
Location
Duration
Category
Award details
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zum Wirkstoff Insulin, normal (human) [zur Aufteilung in Lose siehe bei den Angaben zu den Losen] zu schließen.
Value note
Show original TED data
Original lot title
Insulin, normal (human) (Darreichungsform: Fertigpen)
Original TED description
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zum Wirkstoff Insulin, normal (human) [zur Aufteilung in Lose siehe bei den Angaben zu den Losen] zu schließen.
Procurement Details
- Publication date
- 11 May 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 299317-2025
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Belgium – Pharmaceutical products – Antimycotica
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
France – Pharmaceutical products – 26-10 : ACCORD-CADRE DE FOURNITURE DE MÉDICAMENTS 2026
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
30 / 100
Risk factors
No estimated value or framework maximum available; cannot assess potential revenue.
Procurement documents were not analyzed; key terms (e.g., discount rates, conditions) unknown.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications